Comprehensive Lipid Management Versus Aggressive Low-Density Lipoprotein Lowering to Reduce Cardiovascular Risk

American Journal of Cardiology

Volumn 101, Issue 8 SUPPL. 1, 2008, Pages

  Knopp, Robert H ^a   Paramsothy, Pathmaja ^b   Atkinson, Benjamin ^a   Dowdy, Alice ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; COLESTYRAMINE; ESTROGEN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICERITROL; NICOTINIC ACID; PLACEBO; RESIN; SIMVASTATIN; SLO NIACIN; THYROXINE; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CIRRHOSIS; LIVER TOXICITY; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; NIACIN; RISK FACTORS;

EID: 41049101141     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.038     Document Type: Article

References (31)

1. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
2. Knopp R. The effects of oral contraceptives and postmenopausal estrogens on lipoprotein physiology and atherosclerosis. In: Halbe H., and Rekers H. (Eds). Oral Contraception Into the 1990's (1989), Parthenon Publishing, Carnforth, UK 31-45
3. Knopp R.H., Retzlaff B., Fish B., Walden C., Wallick S., Anderson M., Aikawa K., and Kahn S.E. Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol 23 (2003) 1437-1443
4. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
5. Knopp R.H., Walden C.E., Retzlaff B.M., McCann B.S., Dowdy A.A., Albers J.J., Gey G.O., and Cooper M.N. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA 278 (1997) 1509-1515
6. Knopp R.H., Retzlaff B., Walden C., Fish B., Buck B., and McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc Soc Exp Biol Med 225 (2000) 191-199
7. Parks E.J., and Hellerstein M.K. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 71 (2000) 412-433
8. Kannel W.B., Castelli W.P., and Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90 (1979) 85-91
9. Paramsothy P., Knopp R., Bertoni A., Blumenthal R., Wasserman B., Tsai M., and Heckbert S. Association of lipid phenotype with carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). [abstract #179]. J Coron Artery Dis 7 (2007) 52
10. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
11. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
12. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., and Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
13. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
14. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
15. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
16. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
17. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
18. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., et al., Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
19. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
20. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
21. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
22. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
23. Choi B.G., Vilahur G., Yadegar D., Viles-Gonzalez J.F., and Badimon J.J. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 6 (2006) 571-587
24. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., Yu N., Ansell B.J., Datta G., Garber D.W., and Fogelman A.M. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25 (2005) 1325-1331
25. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
26. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
27. Anantharamaiah G.M., Mishra V.K., Garber D.W., Datta G., Handattu S.P., Palgunachari M.N., Chaddha M., Navab M., Reddy S.T., Segrest J.P., and Fogelman A.M. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 48 (2007) 1915-1923
28. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
29. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
30. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
31. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435